CVS Health Drives Drug Affordability by Promoting Competition

CVS Health's Caremark PBM unit is demonstrating strong market leadership for the 2026 selling season, maintaining high retention rates and securing a significant five-year CalPERS contract for 587,000 members starting in 2026. The company is actively managing drug costs through strategic formulary decisions, such as preferring Wegovy over Zepbound for GLP-1 drugs, anticipating 10-15% annual savings, and previously generating over $1 billion in savings for clients by promoting Humira biosimilars. These initiatives underscore Caremark's ability to drive down prescription costs, contributing to CVS Health's robust year-to-date stock performance, which has surged 67.4%, and its attractive valuation at a forward P/E of 10.87x, below the industry average.

Analysis

CVS Health's Pharmacy Benefit Manager (PBM) unit, Caremark, is demonstrating significant market leadership and strategic execution heading into the 2026 selling season. The unit is sustaining its historical high-90% client retention rate and has secured a major five-year contract with CalPERS to provide drug benefits for approximately 587,000 members, effective January 1, 2026. A key element of Caremark's strategy is aggressive formulary management to control costs, exemplified by its decision to prefer Novo Nordisk's Wegovy over Eli Lilly's Zepbound, a move projected to generate 10-15% annual savings in the anti-obesity drug category. This follows a previous successful strategy of promoting Humira biosimilars, which has already yielded over $1 billion in savings for clients. This operational strength is reflected in the company's financial metrics; CVS shares have surged 67.4% year-to-date, in stark contrast to the industry's 1% decline. Despite this run-up, the stock trades at a forward P/E of 10.87x, which is considerably lower than the industry average of 15.05x, suggesting a potentially attractive valuation. The Zacks Rank #3 (Hold) designation, however, introduces a note of caution, implying that near-term upside may be priced in.

Key Decisions for Investors

• Given the substantial 67.4% year-to-date stock appreciation coupled with a forward P/E of 10.87x that remains below the industry average, investors may consider the current valuation an attractive entry or accumulation point, contingent on continued PBM execution.
• The formulary preference for Wegovy over Zepbound creates a direct headwind for Eli Lilly (LLY) and a tailwind for Novo Nordisk (NVO) in the highly competitive GLP-1 market, presenting a clear thesis for potential relative value trades.
• Investors should monitor Caremark's ability to replicate its cost-saving successes, such as the $1 billion in savings from Humira biosimilars, as this is a primary driver of its competitive advantage and long-term value proposition.
• Despite strong fundamentals, the 'Hold' rating warrants consideration, suggesting that while the long-term outlook is positive, the recent significant share price increase could limit near-term upside without further catalysts.